Ivax (IVX) has received final approval from the Food and Drug Administration to sell a generic version of the cancer treating drug Taxol, which is sold by Bristol-Myers Squibb (BMY) - Get Report.

Trading in Ivax was halted at 1:47 p.m. EDT with the stock last traded at $39.75, down $1.5. Bristol-Myers, meanwhile, was lately up 31 cents to $53.75. The two companies had

tussled over Ivax's desire to introduce paclitaxel, the chemical name for Taxol. The drug is sold by Bristol-Myers for treatment of breast and ovarian cancer, and it has annual global sales of $1.5 billion.

Large pharmaceutical companies have been waging war against drugmakers eager to produce generic versions of popular drugs.

Eli Lilly

TheStreet Recommends

(LLY) - Get Report

earlier fought with

Barr Laboratories

(BRL)

over the latter's desire to produce a generic version of Prozac.